Antibiotic Indications For Resistant Pathogens Could Rely On PK/PD – FDA
Executive Summary
Companies seeking an indication for an antimicrobial agent to treat resistant pathogens could rely mostly on pharmacokinetic and pharmacodynamic studies, FDA said
You may also be interested in...
Antibiotic Research Stalling In Conversion Of Target Into New Drug
Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7
Antibiotic Research Stalling In Conversion Of Target Into New Drug
Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7
Ertaczo Launch Could Help OrthoNeutrogena Rebuild Antifungal Market Share
OrthoNeutrogena's topical athlete's foot treatment Ertaczo gives the company a chance to recapture market share lost to generic versions of another one of its antifungals, Spectazole